Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1255TiP - CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Cytotoxic Therapy;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Dirk De Ruysscher

Citation

Annals of Oncology (2020) 31 (suppl_4): S744-S753. 10.1016/annonc/annonc263

Authors

D. De Ruysscher1, S.S. Ramalingam2, J. Urbanic3, D.E. Gerber4, D.S.W. Tan5, J. Cai6, A. Li7, S. Peters8

Author affiliations

  • 1 Department Of Radiation Oncology (maastro), Maastricht University Medical Center, GROW School for Oncology and Developmental Biology, 6229 ET - Maastricht/NL
  • 2 Department Of Hematology And Medical Oncology, Winship Cancer Institute, Emory University, GA 30322 - Atlanta/US
  • 3 Department Of Radiation Medicine And Applied Sciences, University of California, San Diego, La Jolla/US
  • 4 Division Of Hematology/oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, 75390 - Dallas/US
  • 5 Division Of Medical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 6 Oncology Clinical Development, Bristol-Myers Squibb Company, Princeton/US
  • 7 Biometrics And Data Sciences, Bristol-Myers Squibb Company, Princeton/US
  • 8 Oncology Department, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne University, 1011 - Lausanne/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1255TiP

Background

Historically, the standard-of-care for patients (pts) with unresectable stage III NSCLC was CCRT; however, outcomes are poor with 5-y survival rates of 15–30%. While CCRT primes anti-tumour immunity, it also upregulates PD-L1 expression, potentially blunting any immune response. Thus, concurrent immunotherapy + CCRT may improve outcomes. The safety and tolerability of NIVO, an anti–PD-1 antibody, given concomitantly with CCRT in pts with stage III NSCLC was demonstrated in the phase 2 NICOLAS study (NCT02434081). Furthermore, combining NIVO with IPI, an anti–CTLA-4 antibody, resulted in a longer median overall survival (OS) versus chemotherapy in pts with advanced NSCLC who had a PD-L1 expression level of ≥1% in the phase 3 CheckMate 227 study (NCT02477826). In a prespecified exploratory analysis, NIVO + IPI showed an efficacy benefit versus NIVO. Previously, DURV, an anti–PD-L1 antibody, demonstrated significant improvements versus placebo in progression-free survival (PFS) and OS with manageable safety in pts without disease progression after CCRT in the phase 3 PACIFIC study (NCT02125461). Therefore, we will evaluate the efficacy of NIVO + CCRT followed by NIVO ± IPI versus CCRT followed by DURV for untreated, LA stage III NSCLC in the phase 3 randomized CheckMate 73L study (NCT04026412).

Trial design

In all, 888 pts aged ≥18 y with previously untreated stage III NSCLC and an ECOG PS ≤1 will be stratified by age, PD-L1 expression, and disease stage, then randomized (1:1:1) to receive NIVO (360 mg Q3W) + CCRT followed by NIVO (360 mg Q3W) + IPI (1 mg/kg Q6W; Arm A) or NIVO alone (480 mg Q4W; Arm B) for ≤1 y, or CCRT followed by DURV (10 mg/kg Q2W; Arm C) for ≤1 y. Pts with PD during CCRT will discontinue treatment and enter follow-up. Primary endpoints are PFS by RECIST 1.1, assessed by BICR (Arm A vs C) and OS (Arm A vs C). Secondary endpoints are PFS (Arm B vs A or C), OS (Arm B vs A or C), objective response rate, time to response, duration of response, time to distant metastases, and safety. Start date: Aug 2019.

Clinical trial identification

NCT04026412; July 19, 2019.

Editorial acknowledgement

Writing and editorial assistance was provided by Simon Wigfield, PhD, of Caudex, funded by Bristol-Myers Squibb Company.

Legal entity responsible for the study

Bristol-Myers Squibb Company.

Funding

Bristol-Myers Squibb Company.

Disclosure

D. De Ruysscher: Honoraria (institution): Bristol-Myers Squibb Company, Celgene, Merck/Pfizer, Roche/Genentech, AstraZeneca, MSD, Seattle Genetics; Advisory/Consultancy, To institution: Bristol-Myers Squibb Company, Celgene, Merck/Pfizer, Roche/Genentech, AstraZeneca, MSD, Seattle Genetics; Research grant/Funding (institution): Boehringer Ingelheim, Bristol-Myers Squibb Company. AstraZeneca, Philips, Olink. S.S. Ramalingam: Advisory/Consultancy: Amgen, AbbVie, Bristol-Myers Squibb Company, Genentech/Roche, Merck, AstraZeneca, Takeda; Research grant/Funding (institution): Advaxis, Amgen, AstraZeneca, Bristol-Myers Squibb Company, Merck, Takeda, Tesaro. D.E. Gerber: Advisory/Consultancy: Catalyst Pharmaceuticals; Research grant/Funding (institution): AstraZeneca, BerGenBio, Karyopharm, 3V Biosciences; Shareholder/Stockholder/Stock options: Gilead; Non-remunerated activity/ies: Bristol-Myers Squibb Company, Karyopharm. D.S.W. Tan: Honoraria (self): Boehringer Ingelheim, Merck, Roche, Pfizer, Novartis, Takeda; Advisory/Consultancy: Novartis, Bayer, Boehringer Ingelheim, Celgene, AstraZeneca, Eli Lilly, Loxo, Pfizer, Takeda, Merrimack; Research grant/Funding (self): Novartis, Bayer, AstraZeneca, GlaxoSmithKline, Pfizer; Travel/Accommodation/Expenses: Pfizer, Takeda, Boehringer Ingelheim, Novartis, Merck. J. Cai: Full/Part-time employment: Bristol-Myers Squibb Company. A. Li: Full/Part-time employment: Bristol-Myers Squibb Company. S. Peters: Honoraria (institution), Advisory/Consultancy: AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Bioinvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Janssen, Merck Sharp & Dohme Corp., M; Research grant/Funding (institution): Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche, Illumina, Merck Sharp & Dohme Corp., Merck Serono, Novartis, Pfizer; Travel/Accommodation/Expenses, Travel for adboards/meetings: AstraZeneca, Bayer, Bristol-Myers Squibb, F. Hoffmann-La Roche, Foundation Medicine, Illumina, Merck Sharp & Dohme Corp., Pfizer, Seattle Genetics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.